Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
0.060 Biomarker disease BEFREE While no phenotypic changes were observed for MIA PaCa-2-passaged viruses, both SUIT-2-passaged VSV-p53wt and VSV-p53-CC showed improved replication in SUIT-2 and AsPC-1, another human PDAC cell line also moderately resistant to VSV, while remaining highly attenuated in non-malignant cells. 31694943 2020
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
0.060 Biomarker disease BEFREE The viability and proliferation of primary (PANC-1 and MIA PaCa-2) and metastatic (SW1990 and ASPC-1) PDAC cell lines treated with L48H37 was determined by CCK8 and colony formation assay. 31435462 2019
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
0.060 Biomarker disease BEFREE Moreover, the inhibitory effect of CXCR2 antagonist on PDAC cell proliferation was more powerful in MIA PaCa-2 cells than CFPAC-1 cells. 28214673 2017
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
0.060 Biomarker disease BEFREE Here, we assessed the sensitivities of BRCA2-deficient (Capan-1) and BRCA2-proficient (MIA PaCa-2) PDAC cell lines to a panel of DCLs and PARPis. 25864590 2015
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
0.060 Biomarker disease BEFREE We combined data from miRNA and messenger RNA (mRNA) expression profiles and bioinformatic analyses to identify an miRNA-mRNA regulatory network in PDAC cell lines (PANC-1 and MIA PaCa-2) and in PDAC samples from patients. 24120476 2014
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
0.060 Biomarker disease BEFREE Treatment of PDAC cell lines BxPC-3 and MIA PaCa-2 with a specific HDAC inhibitor, trichostatin A (TSA), strongly activates TbetaRII promoter activity and induces TbetaRII expression. 12750289 2003